Universal Beteiligungs und Servicegesellschaft mbH Takes $350,000 Position in Pediatrix Medical Group, Inc. $MD

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Pediatrix Medical Group, Inc. (NYSE:MD) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,406 shares of the company’s stock, valued at approximately $350,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Allianz Asset Management GmbH grew its position in shares of Pediatrix Medical Group by 159.1% in the 2nd quarter. Allianz Asset Management GmbH now owns 61,412 shares of the company’s stock worth $881,000 after buying an additional 37,712 shares during the period. Russell Investments Group Ltd. lifted its position in Pediatrix Medical Group by 2.9% during the 1st quarter. Russell Investments Group Ltd. now owns 219,184 shares of the company’s stock valued at $3,176,000 after acquiring an additional 6,127 shares during the period. Strs Ohio bought a new stake in Pediatrix Medical Group during the first quarter worth about $690,000. Counterpoint Mutual Funds LLC bought a new stake in Pediatrix Medical Group during the second quarter worth about $755,000. Finally, Wakefield Asset Management LLLP purchased a new stake in Pediatrix Medical Group in the second quarter worth about $1,002,000. Institutional investors own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MD shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Tuesday. Truist Financial raised their price objective on Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Zacks Research raised Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a report on Friday, November 21st. UBS Group increased their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Finally, Leerink Partners lifted their price target on Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Pediatrix Medical Group Stock Performance

Shares of MD opened at $23.97 on Friday. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 18.58 and a beta of 1.20. The business’s fifty day simple moving average is $19.27 and its two-hundred day simple moving average is $16.17. Pediatrix Medical Group, Inc. has a 12 month low of $11.84 and a 12 month high of $24.99. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The firm had revenue of $492.88 million during the quarter, compared to analysts’ expectations of $476.45 million. During the same quarter in the previous year, the business earned $0.44 earnings per share. The company’s revenue was down 3.6% on a year-over-year basis. Research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In related news, Director Michael A. Rucker sold 10,478 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $23.00, for a total transaction of $240,994.00. Following the transaction, the director owned 59,101 shares in the company, valued at $1,359,323. This represents a 15.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura A. Linynsky sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $21.65, for a total transaction of $216,500.00. Following the completion of the sale, the director owned 32,232 shares in the company, valued at $697,822.80. This represents a 23.68% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.90% of the company’s stock.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.